SCHEMBL29865803

SCHEMBL29865803

CN(Cc1nccnc1-c1ccnc(Cl)c1F)C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SSTR4 P31391 1/20 0.43
▸ AAK1 Q2M2I8 5/20 0.40
▸ HTR2C P28335 6/20 0.37
▸ SLC6A4 P31645 6/20 0.37
▸ GPBAR1 Q8TDU6 1/20 0.36
▸ ATR Q13535 1/20 0.34
▸ KAT6A Q92794 2/20 0.34
▸ KAT5 Q92993 2/20 0.34
▸ CACNA1G O43497 1/20 0.33
▸ CACNA1B Q00975 1/20 0.33
▸ CACNA1C Q13936 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ PDK2 Q15119 1/20 0.32
▸ TACR1 P25103 1/20 0.32
▸ KAT8 Q9H7Z6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29865848 0.86 AAK1 (0.39) SSTR4AAK1HTR2CSLC6A4GPBAR1
SCHEMBL25573077 0.85 SSTR4 (0.39) SSTR4AAK1HTR2CSLC6A4GPBAR1
SCHEMBL25573086 0.84 SSTR4 (0.38) SSTR4AAK1HTR2CSLC6A4GPBAR1
SCHEMBL29866395 0.83 SSTR4 (0.37) SSTR4AAK1HTR2CSLC6A4GPBAR1
SCHEMBL30697036 0.81 HTR2C (0.41) SSTR4AAK1HTR2CSLC6A4GPBAR1
SCHEMBL25897403 0.81 HTR2C (0.40) SSTR4AAK1HTR2CSLC6A4GPBAR1
SCHEMBL29865899 0.81 SSTR4 (0.40) SSTR4HTR2CSLC6A4ATRCACNA1G
SCHEMBL30696915 0.81 AAK1 (0.41) SSTR4AAK1HTR2CSLC6A4GPBAR1
SCHEMBL30697082 0.81 AAK1 (0.37) SSTR4AAK1HTR2CSLC6A4GPBAR1
SCHEMBL29865893 0.79 SSTR4 (0.38) SSTR4HTR2CSLC6A4CACNA1GCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600721-B2 TYK2 inhibitors and uses thereof SUDO BIOSCIENCES LIMITED (GB) 2026-04-14 — — US disclosed
US-20240199610-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LIMITED (GB) 2024-06-20 — — US disclosed
EP-4294806-A1 TYK2 INHIBITORS AND USES THEREOF Sudo Biosciences Limited (GB) 2023-12-27 — — EP disclosed
WO-2022175746-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LIMITED (GB) 2022-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600721-B2 TYK2 inhibitors and uses thereof TYK2, CSNK2A3, JAK1 SSTR4 2451/4885AAK1 691/4885HTR2C 668/4885
US-20240199610-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 SSTR4 4782/4885AAK1 165/4885HTR2C 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback